Porse B T, Garrett R A
RNA Regulation Centre, Institute of Molecular Biology, University of Copenhagen, Solvgade 83H, Copenhagen K, DK1307, Denmark.
J Mol Biol. 1999 Feb 19;286(2):375-87. doi: 10.1006/jmbi.1998.2509.
Streptogramin antibiotics contain two active A and B components that inhibit peptide elongation synergistically. Mutants resistant to the A component (virginiamycin M1 and pristinamycin IIA) were selected for the archaeon Halobacterium halobium. The mutations mapped to the universally conserved nucleotides A2059 and A2503 within the peptidyl transferase loop of 23 S rRNA (Escherichia coli numbering). When bound to wild-type and mutant haloarchaeal ribosomes, the A and B components (pristinamycins IIA and IA, respectively) produced partially overlapping rRNA footprints, involving six to eight nucleotides in the peptidyl transferase loop of 23 S rRNA, including the two mutated nucleotides. An rRNA footprinting study, performed both in vivo and in vitro, on the A and B components complexed to Bacillus megaterium ribosomes, indicated that similar drug-induced effects occur on free ribosomes and within the bacterial cells. It is inferred that position 2058 and the sites of mutation, A2059 and A2503, are involved in the synergistic inhibition by the two antibiotics. A structural model is presented which links A2059 and A2503 and provides a structural rationale for the rRNA footprints.
链阳性菌素类抗生素包含两种活性A和B组分,它们协同抑制肽链延伸。为嗜盐古菌盐生盐杆菌筛选出了对A组分(维吉尼亚霉素M1和 pristinamycin IIA)耐药的突变体。这些突变定位于23S rRNA肽基转移酶环内普遍保守的核苷酸A2059和A2503(大肠杆菌编号)。当分别与野生型和突变型嗜盐古菌核糖体结合时,A和B组分(分别为pristinamycins IIA和IA)产生部分重叠的rRNA足迹,涉及23S rRNA肽基转移酶环中的六到八个核苷酸,包括两个突变的核苷酸。对与巨大芽孢杆菌核糖体复合的A和B组分进行的体内和体外rRNA足迹研究表明,在游离核糖体和细菌细胞内会出现类似的药物诱导效应。据推测,位置2058以及突变位点A2059和A2503参与了这两种抗生素的协同抑制作用。本文提出了一个结构模型,该模型将A2059和A2503联系起来,并为rRNA足迹提供了结构依据。